Johnson & Johnson (JNJ) price target and intrinsic value estimate is $164.7.

Johnson & Johnson together with its subsidiaries researches develops manufactures and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas such as immunology including rheumatoid arthritis psoriatic arthritis inflammatory bowel disease and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience consisting of mood disorders neurodegenerative disorders and schizophrenia; oncology such as prostate cancer hematologic malignancies lung cancer and bladder cancer; cardiovascular and metabolism including thrombosis diabetes and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers wholesalers distributors hospitals and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips knees trauma spine sports and other; surgery portfolios comprising advanced and general surgery technologies as well as solutions for breast aesthetics ear nose and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers hospitals and retailers as well as physicians nurses hospitals eye care professionals and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick New Jersey.